Status:

COMPLETED

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Lead Sponsor:

TWi Biotechnology, Inc.

Conditions:

Gout

Eligibility:

All Genders

20-65 years

Phase:

PHASE2

Brief Summary

The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the comb...

Detailed Description

AC-201CR is a control released formulation of AC-201 that in previous clinical studies showed potential dual effects in both reducing serum uric acid (sUA) and gout flares. The mechanism of action of ...

Eligibility Criteria

Inclusion

  • Male or female age 20 to 65 years, inclusive.
  • Meets ≥6 of the 12 American College of Rheumatology preliminary criteria (1977) for the classification of acute arthritis of primary gout (Appendix 2), OR have proven tophus or documented monosodium urate (MSU) crystals in the joint fluid.
  • Serum uric acid ≥7.5 mg/dL and ≤10 mg/dL at screening with ≥1 gouty arthritis flare within one year prior to screening, OR serum uric acid ≥9 mg/dL and ≤10 mg/dL at screening with or without prior gout flares.

Exclusion

  • Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2 weeks prior to screening.
  • Occurrence of a gouty arthritis flare within 1 week prior to screening or during the screening period through baseline.
  • Use of colchicine within 1 week prior to screening.
  • Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening.
  • Allergy, contraindication, or intolerance to febuxostat.
  • Severe renal impairment.
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration \>2 times the upper limit of laboratory normal range (\>2x ULN) at screening.

Key Trial Info

Start Date :

December 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 27 2016

Estimated Enrollment :

127 Patients enrolled

Trial Details

Trial ID

NCT02287818

Start Date

December 1 2014

End Date

October 27 2016

Last Update

June 28 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Taipei Veteran General Hospital (TVGH)

Taipei, Taiwan, 112